Otonomy To Challenge Multi-Dose Ear Drops With Otiprio Expansion Plans
Otonomy will file for expanded US approval of Otiprio for use in swimmer’s ear on the back of positive top-line Phase III data – the product has the potential to improve on current treatments in terms of dosing, and the news sent its share price up by more than 10%.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Merck's Follow-On Insulin Edges Closer To Market; Braeburn Submits Another Buprenorphine Depot
The latest drug development news and highlights from our FDA Performance Tracker.
While its NDA languishes at the US Food and Drug Administration, the EMA’s CHMP has said yes to dostarlimab’s marketing in the EU for endometrial cancer.